ARTICLES BY LOUIS

• Can This Outsourcing Model Save Health Care?

  7/15/2015

  A company has been formed to push aside the intermediaries standing between new drugs and the patients that need them. In the process, says Cynthia LaConte, CEO of Dohmen Life Science Services, this model of “intelligent outsourcing” will start to improve health care efficiencies and lower costs.

• An All-Outsourcing Model For Orphan Drugs

  6/15/2015

  Nils U. Olsson, VP of Chemistry, Manufacturing and Controls at Retrophin Inc., says his company’s business model targeting new drugs for orphan diseases allows for a perfect application of an all-outsourcing strategy. 

• Silicon Valley Targets CRO Industry For Market Disruption

  5/22/2015

  The techies in Silicon Valley are at it again. This time it’s the contract research industry targeted for disruption. “We now look at the Science Exchange as the best way of finding new outsourcing opportunities,” says James Lillie, VP In Vitro Biology, Genzyme.  Will other research sponsors and CROs lose out on new opportunities if they don’t, too?

• CROs/CMOs Powering Vaccine R&D At Biotechs

  5/18/2015

  There’s a vitality in in the biotech space, supported in large part by CROs/CMOs, for vaccine innovation. Where does that intersect with the troubled commercial-scale vaccine market? And if commercialization leads to a low-margin future, even if biotechs can fill the innovation gap, why would they want to?  

• Sanofi Pasteur: Vaccine Ecosystem In Danger

  5/12/2015

  The intent was to investigate outsourcing in the innovative vaccine industry. However, it became obvious we’d first need to decipher a Kafkaesque world of organizations and markets. “There are strong warning signs out there,” says Michael Watson, VP of Global Immunization Policy, Sanofi Pasteur.

• Adare Pharmaceuticals Business Model Steady Through the Rodeo

  5/5/2015

  Here's a partnering business-model well-suited to the dug development strategies of biotechnology and pharmaceutical companies, as well as the court of public opinion.

• Not a Sterile Debate On Aseptic Services Crunch

  5/4/2015

  Driving the aseptic services sector is positive news, but with a side effect: the breakthroughs in biologics and other increasingly complex products are enabling the creation of exciting new drugs and therapies … but all requiring the “right” capacity and “perfect" compliance at aseptic facilities.

• Amgen Three-Deep With Suppliers; Lilly “Making Medicine Together”

  4/17/2015

  Bill Rich, VP, External Supply, Amgen, says pharma is duty-bound to monitor the supply chain down to “our suppliers’ suppliers’ suppliers.” For his part, Craig Michael, Director External API Manufacturing, Eli Lilly and Company, says the whole supply chain needs to say, believe and act as, "I make medicine."

• Pharma's New Partner At Regulatory and Legislative Tables

  4/13/2015

  Pharma should take this organization as a sign the CMO/CDMO industry is maturing. It’s taking itself seriously, and moving forward as an important sector of the healthcare industry.

• Gilead Saves Lives And Healthcare Dollars By Taking Profits

  4/6/2015

  It’s affordable worldwide, saves lives and healthcare dollars, allows a company to create more innovative drugs, and validates the biotech business model. Why a negative bias?